Medical tampon could detect early signs of ovarian cancer

Researchers in Southampton are set to begin a trial of a revolutionary medical tampon that may detect early signs of ovarian cancer, a disease diagnosed in approximately 7,600 UK residents annually with many cases identified at advanced stages. The study, named 'Violet,' will recruit 250 women including those diagnosed with ovarian cancer scheduled for ovary removal and carriers of the BRCA gene mutation who opt for risk-reducing surgery. Developed by biotechnology company Daye, the innovative device identifies biological signals in vaginal fluid that could potentially identify tumors at earlier stages, addressing the current lack of screening programs for ovarian cancer. Dr. Jemma Longley, chief investigator and consultant medical oncologist at University Hospital Southampton, emphasized that the current preventive surgery for high-risk women can lead to significant long-term health effects by inducing surgical menopause in younger patients. The diagnostic tampon represents a potential breakthrough in ovarian cancer detection, which currently lacks a reliable screening method. Ovarian cancer often presents with non-specific symptoms in both early and late stages, allowing tumors to spread silently to other organs. This characteristic makes early detection particularly challenging and contributes to the high mortality rate associated with the disease. If successful, the tampon could revolutionize how ovarian cancer is detected, potentially saving numerous lives through earlier intervention. The trial will focus on analyzing vaginal fluid for biological signals that indicate the presence of early-stage tumors. David Constable-Phelps, a co-investigator and consultant gynaecological oncology surgeon, expressed optimism that the study will identify these signals, which would 'be a complete game-changer for women with ovarian cancer.' The researchers hope that this initial trial will pave the way for larger studies and eventually lead to a widely available screening method. The development of such a screening tool would significantly reduce the need for preventive surgeries and their associated complications, particularly for younger women with genetic predispositions to the disease.